Private label formula ownership: what you actually own and how to protect it

Most brands that commission private label supplements assume they own the formula. They paid for the development. They specified the ingredients. The product carries their name. Surely it belongs to them. In most contracts, this assumption is wrong. Formula ownership is a specific legal concept that must be explicitly negotiated and written into the manufacturing agreement. Without that, the manufacturer owns the formula regardless of who paid for it.

This matters when you try to switch manufacturers, when a manufacturer goes out of business, when you prepare for an acquisition, or when a competitor copies your bestseller and the only way to stop them is to prove you own the IP. This guide breaks down the three tiers of formula ownership, the key contract clauses, the difference between IP assignment and license, and how to negotiate ownership before you spend a euro on development.

Three tiers of ownership

Formula ownership in the supplement industry is not binary. It exists on a spectrum, and where you land depends on what type of product you commissioned and what your contract says.

Tier one: stock white label — no ownership

You have no claim to the formula. The manufacturer developed it, and they sell it to multiple brands. Your contribution was selecting it and applying your label. You own the brand. You do not own anything about the product formulation. If you want to move to a different manufacturer, you start from scratch. Your packaging design, your claims, your label layout — those are yours. The formula is not.

Tier two: modified private label — partial ownership

You took a base formula and modified it — adjusted a dosage, swapped an ingredient form, added a functional ingredient, changed the excipient profile. You paid for the modification. You may have a legitimate claim to the modifications you funded, but the underlying base formula still belongs to the manufacturer. In practice, partial ownership is difficult to enforce and difficult to transfer. Most contracts in this tier give you exclusivity for a defined period and territory, but not formula ownership. You can prevent competitors from ordering the same modified formula from the same manufacturer, but you cannot take the specification to a different factory.

Tier three: custom formula — full ownership

The formula was developed from scratch to your brief, using your investment. With the right contract clauses, you can own the full formula specification: the ingredient list, the ratios, the manufacturing parameters, the testing protocols. This ownership can be transferred to a new manufacturer. It can be sold. It can be licensed. It is genuine IP. This tier requires explicit IP assignment language in the contract, development fees paid by you, and in most cases a higher initial production commitment from the manufacturer in exchange for granting ownership.

What is actually in contracts

Manufacturing agreements for private label supplements typically contain several clauses that determine your actual IP position. Most founders never read these clauses carefully until there is a problem.

Exclusivity clauses

Exclusivity means the manufacturer agrees not to sell the same or substantially similar formula to other brands in a defined territory for a defined period. Exclusivity is not ownership. Your formula may be exclusive to you in Germany for three years — but the manufacturer still owns it. They can sell it elsewhere, modify it for other clients, or use it as the basis for a new product line after your exclusivity period expires. Read exclusivity clauses carefully: look for the territorial scope (EU-wide? Single country?), the duration, the definition of "substantially similar," and what happens when the exclusivity period ends.

IP assignment vs license

These are the two fundamentally different ways a manufacturer can grant you rights to a formula. An IP assignment transfers ownership of the formula to you. After the assignment, the manufacturer does not own it anymore. You can take the specification to a competing factory. You can sell it. You can license it. An IP license lets you use the formula, but the manufacturer retains ownership. The license may be exclusive and perpetual — which sounds like ownership — but it is not. If the manufacturer goes bankrupt, the license may terminate. If you want to transfer the license to a new entity (a buyer in an acquisition), you may need the manufacturer's consent. Always ask for assignment, not license, for your hero products. Expect to pay more for it.

COA access and specification documents

A Certificate of Analysis (COA) confirms what is in the product. A formula specification document lists the ingredients, ratios, and manufacturing parameters in enough detail to reproduce the product at another factory. Owning the IP in legal terms is not sufficient if you do not have the specification documents. Include a clause that requires the manufacturer to provide complete formula specifications, batch records, and stability data to you upon request, or at minimum upon termination of the agreement. Without this, ownership is nominal.

Modification rights

If you own the formula, do you have the right to modify it? And if you modify it, who owns the modified version? Some contracts grant formula ownership but restrict your right to modify without the original manufacturer's consent — effectively locking you to them even though you technically own the base formula. Negotiate clean modification rights: you should be free to modify the formula at any manufacturer, with full ownership of the modifications, without needing the original manufacturer's permission.

Exit clauses

What happens to the formula ownership if you stop ordering? Some contracts include reversion clauses: if your purchase volume falls below a minimum threshold, or if you do not reorder within a defined period, formula ownership reverts to the manufacturer. These clauses are common and legitimate — manufacturers do not want to lock their formula into an inactive relationship — but you need to understand the trigger conditions and negotiate them to match your realistic production cycles.

When formula ownership actually matters

Not every product is worth owning. Formula ownership negotiation is a meaningful investment of time, legal fees, and development costs. It pays off in specific circumstances.

The practical threshold is a hero product generating above EUR 1 million in annual revenue, with strong repeat purchase rates and a product formulation that contributes meaningfully to the brand's positioning. Below that level, the transaction costs of acquiring and protecting formula ownership exceed the likely benefit.

• Manufacturer risk. If your main manufacturer experiences capacity problems, quality failures, or goes out of business, formula ownership lets you move production to a backup supplier without rebuilding the formula from scratch. For any product doing meaningful volume, this business continuity argument alone justifies the ownership investment.
• Competitive defense. If a competitor finds your supplier and orders a similar product, formula ownership combined with the right exclusivity clauses gives you a legal basis to defend your position. Without it, you are relying purely on your brand to differentiate from a product with an identical or near-identical formula.
• Acquisition readiness. Acquirers perform IP due diligence. A brand with proprietary formulas, ownership documentation, and clean chain-of-title IP is worth significantly more than one built on licensed or white label products. If you are building to sell, start acquiring formula ownership on your top performers early.

How to negotiate

Formula ownership is not a standard term in most manufacturing agreements. You have to ask for it explicitly, and you have to be prepared to pay for it. The negotiation happens before development begins — once the manufacturer has already developed the formula, your leverage is lower.

Specific clauses to include in the manufacturing agreement:

• "All intellectual property in the formula, including but not limited to ingredient ratios, manufacturing specifications, and stability data, is hereby assigned to [Brand Name] upon payment of development fees."
• "Manufacturer will provide complete formula specifications, manufacturing parameters, and relevant quality documentation to Brand Name within 30 days of written request."
• "Brand Name has the right to manufacture or have manufactured the product at any facility, without restriction, using the assigned formula specification."
• "This assignment is irrevocable and does not terminate upon cessation of orders or expiration of this agreement."

Budget reality: acquiring full formula ownership for a modified formula typically costs EUR 10,000 to EUR 50,000 in development fees, depending on the complexity of the modification and the manufacturer's pricing for IP assignment. Custom novel formulas with full IP assignment can cost EUR 30,000 to EUR 100,000 when stability studies, regulatory documentation, and legal review are included. These are real numbers for EU supplement manufacturers working with professional brands.

Some manufacturers will not grant full assignment regardless of price. They view their formulas as proprietary assets. In those cases, push for the strongest possible license: exclusive, perpetual, irrevocable, sublicensable, and transferable without the manufacturer's consent. A well-structured license is not as clean as assignment, but it is substantially better than a standard exclusivity clause.

Common mistakes

• Assuming ownership without a contract. The most common mistake. A brand commissions a formula, pays the development fees, and operates for years believing they own the product. When they try to switch manufacturers or sell the business, they discover the contract never addressed IP assignment. There is no implied ownership in supplement manufacturing — if it is not in the contract, the manufacturer owns it.
• Confusing exclusivity with ownership. Exclusivity means the manufacturer will not sell the same formula to your competitors in your territory. It does not mean you own the formula. These are different protections with different limitations. Many founders conflate them until the distinction becomes painful — usually when they want to move production.
• Vague exclusivity language. Exclusivity clauses that do not define "substantially similar" are nearly unenforceable. A manufacturer can modify your formula by 5% and argue it is a different product. Require specific language: the exclusivity applies to any formula that contains the same five key active ingredients at dosages within 15% of your specification, in the same delivery format, for the same primary health claim category.
• Not securing specification documents. Owning the formula legally without having the manufacturing specification is a hollow right. Make sure your contract includes an obligation to deliver all technical documentation, not just a legal assignment of IP.
• Negotiating ownership after launch. Once a product is in market and selling, the manufacturer knows how valuable it is. Their willingness to grant ownership at a reasonable price decreases. Negotiate ownership terms before development begins, when you still have full optionality.

Quick FAQ

If I paid for formula development, do I automatically own the formula?

No. Payment for development services does not transfer IP ownership unless the contract explicitly says so. Under most European IP frameworks, the creator of a work owns it unless there is a written agreement that assigns ownership to the commissioning party. Always require a written IP assignment clause as a condition of the development agreement. Do not start paying development fees until this clause is agreed and signed.

What is the difference between a perpetual exclusive license and full ownership?

In practice, a well-drafted perpetual exclusive license with transfer rights can approximate ownership for most operational purposes. The key differences that matter: in bankruptcy proceedings, a license may be treated differently from owned IP; in an acquisition, buyers often prefer clean ownership title and may require the manufacturer's consent to transfer a license; and in litigation, establishing the scope of your rights is cleaner with assignment than with a license. Where possible, push for assignment. Where assignment is not available, negotiate the strongest possible license terms.

Can I take a formula owned by my manufacturer to another factory?

Only if your contract gives you that right. Without explicit permission in the contract, using a formula owned by your manufacturer at a competing facility is a breach of contract and potentially an IP infringement. If your contract only grants exclusivity (not ownership), you cannot move production. If your contract grants full assignment, you can take the specification anywhere. This is one of the most operationally important distinctions between ownership and exclusivity.

How long does it take to develop a custom formula with full IP assignment?

From brief to production-ready product with completed stability studies: 18 to 36 months for a genuinely novel formula in a regulated category. Modified formulas with a shorter stability pathway can be done in 12 to 18 months. The IP assignment itself adds no time to the process — it is a contractual term agreed at the start. The time is in formulation, stability testing, and regulatory review. Plan accordingly: if you need the product on shelf by a specific date, work backward from that date and do not start the IP negotiation late.

Should every product in my range have formula ownership?

No. Formula ownership is a significant investment. Apply it strategically: to your hero products, to your highest-margin SKUs, and to any product where the formula itself is a meaningful differentiator. For the rest of your catalog, a well-negotiated exclusivity clause is sufficient. Focus your IP investment where it generates the most return — typically one to three products per brand. Trying to own every formula in a 15-SKU range is an expensive mistake that most brands do not need to make.